<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01814800</url>
  </required_header>
  <id_info>
    <org_study_id>ADMA-003</org_study_id>
    <nct_id>NCT01814800</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)</brief_title>
  <official_title>An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADMA Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADMA Biologics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, open-label study of RI-002 administered as an intravenous
      infusion of RI-002 (IGIV) every 21 or 28 days in approximately 60 subjects with Primary
      Immunodeficiency Diseases (PIDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary immunodeficiency diseases (PIDDs) are genetically determined disorders of the immune
      system resulting in greatly enhanced susceptibility to infectious disease, autoimmunity and
      malignancy. As most subjects with PIDDs present with infections, the differential diagnosis
      and initial investigations for an underlying immune defect are typically guided by the
      clinical presentation. In subjects with PIDDs, individual infections are not necessarily more
      severe than those that occur in a normal host. Rather, the clinical features suggestive of an
      immune defect may be the recurring and/or chronic nature of infections with common pathogens
      that may result in end organ damage, such as bronchiectasis. Several immune globulin products
      have already been approved by the FDA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))</measure>
    <time_frame>One year</time_frame>
    <description>The primary objective of this study was to demonstrate that RI-002 (IGIV) reduces the frequency of serious bacterial infections (SBIs), as defined by the Diagnostic Criteria for Serious Infection Types guideline, in subjects with primary humoral immunodeficiency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Infections (Serious and Non-serious)</measure>
    <time_frame>Up to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Combined Days Lost</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Per Subject-Year</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unscheduled Visits to Physician/ER Due to Infections - Total Number of Visits</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unscheduled Visits to Physician/ER Due to Infections - Per Subject-Year</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Infections - Duration Per Infection</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Infections - Infection Days Per Subject</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations Due to Infections</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations Due to Infections - Per Subject-Year</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Hospitalization Due to Infections</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Hospitalization Due to Infections - Per Subject-Year</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of the days of antibiotic therapy in the study for prophylaxis, as treatment for infections, and combined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection) - Per Subject-Year</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of the days of antibiotic therapy in the study for prophylaxis, as treatment for infections, and combined, per subject-year of treatment with RI-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Trough Level of RI-002 and Serious and Non-serious Infections</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The relationship between trough IgG concentrations and the number of infections of any kind/seriousness was evaluated using Pearson linear correlation coefficients using forward analysis (outcomes after infusion) and backward analysis (outcomes prior to infusion; outcomes post last infusion were excluded)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - IgG</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough total IgG concentration prior to specified infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Haemophilus Influenzae Type B</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Haemophilus influenzae type B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Respiratory Syncytial Virus (RSV)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Respiratory Syncytial Virus (RSV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Tetanus</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Tetanus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 1</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 3</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 4</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 5</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 6B</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 6B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 7F</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 7F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 9V</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 9V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 14</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 18C</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 18C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19A</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 19A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19F</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 19F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 23F</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 23F</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>RI-002 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RI-002</intervention_name>
    <description>Immune Globulin Intravenous (IGIV)</description>
    <arm_group_label>RI-002 Treatment</arm_group_label>
    <other_name>Immune Globulin (Human)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible to participate in this study, the subjects must meet the following criteria:

          1. Signed a written informed consent or a specific assent form for minors.

          2. Have a diagnosis of primary immunodeficiency disease.

          3. Be ≥ 2 years and ≤ 75 years.

          4. Have body weight ≥ 12 kg at screening.

          5. Have been receiving IGIV at a dose that has not been changed by &gt;50% of the mean dose
             on a mg/kg basis for at least 3 months prior to study entry and have maintained a
             trough serum Immunoglobulin G (IgG) level ≥ 500 mg/dL on the previous 2 assessments
             prior to receiving RI 002. The trough level must be at least 300 mg/dL above the
             pre-treatment serum IgG level.

          6. For female subjects, be of non-childbearing potential or have a negative pregnancy
             test prior to study start and be deemed not at risk of becoming pregnant by adherence
             to a reliable contraceptive method for the duration of the study.

        Exclusion Criteria:

        Subjects must be excluded if they meet any of the following criteria:

          1. Have a known hypersensitivity to immunoglobulin or any excipient in RI-002.

          2. Have a history of a severe anaphylactic or anaphylactoid reaction to blood or any
             blood-derived product.

          3. Have a specific Immunoglobulin A (IgA) deficiency, history of allergic reaction to
             products containing IgA or has demonstrable antibodies to IgA.

          4. Have uncompensated hemodynamically significant congenital or other heart disease.

          5. Have a medical condition that is known to cause secondary immune deficiency.

          6. Have a significant T-cell deficiency or deficiency of granulocyte number or function.

          7. Have significant renal impairment or have a history of acute renal failure.

          8. Have abnormal liver function.

          9. Be receiving chronic anti-coagulation therapy.

         10. Have a history of deep vein thrombosis (DVT), thrombotic or thrombo-embolic event, or
             are at increased risk for thrombotic events.

         11. Current daily use of the following medications:

               -  corticosteroids (&gt; 7.5 mg (or equivalent dose on a mg/kg basis) of prednisone
                  equivalent per day for &gt; 30 days)

               -  immunomodulatory drugs

               -  immunosuppressive drugs (excluding topical pimecrolimus (Elidel) and tacrolimus
                  (Protopic))

         12. Administration of a hyperimmune or specialty high titer immunoglobulin product.

         13. Have uncontrollable arterial hypertension.

         14. Have a history of hemolysis or positive Coombs test while undergoing treatment with
             IGIV therapy.

         15. Be morbidly obese as indicated by a Body Mass Index (BMI) ≥ 40

         16. Have received any blood product (other than Immunoglobulin G) within 3 months prior to
             screening.

         17. Have received any Respiratory Syncytial Virus (RSV) specific products, including
             palivizumab (Synagis®) within 3 months prior to screening.

         18. Have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within
             the past 12 months.

         19. Have any condition or abnormal laboratory assessment judged by the investigator to
             preclude participation in the study.

         20. Are currently pregnant or nursing.

         21. Have hepatitis A, B, or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Mond, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>ADMA Biologics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMMUNOe Health Centers</name>
      <address>
        <city>Cenntennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches, P.A.</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy Center, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The South Bend Clinic, LLP</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Immunology Associates</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Immunology Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <results_first_submitted>December 15, 2015</results_first_submitted>
  <results_first_submitted_qc>August 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2016</results_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIDD, PID, humoral immunity, antibody deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RI-002 Treatment</title>
          <description>Drug: RI-002 Dose: 300-800 mg/kg IV infusion Frequency: Every 3 or 4 weeks
Initial dose selection based on prior IGIV regimen, doses adjusted during study to maintain trough Immunoglobulin G (IgG) concentration of 500 mg/dL or greater according to investigator decision.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RI-002 Treatment</title>
          <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" lower_limit="3" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PIDD Type</title>
          <description>Primary PIDD diagnosis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Common Variable Immunodeficiency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-Linked Agammaglobulinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody Deficiencies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))</title>
        <description>The primary objective of this study was to demonstrate that RI-002 (IGIV) reduces the frequency of serious bacterial infections (SBIs), as defined by the Diagnostic Criteria for Serious Infection Types guideline, in subjects with primary humoral immunodeficiency.</description>
        <time_frame>One year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))</title>
          <description>The primary objective of this study was to demonstrate that RI-002 (IGIV) reduces the frequency of serious bacterial infections (SBIs), as defined by the Diagnostic Criteria for Serious Infection Types guideline, in subjects with primary humoral immunodeficiency.</description>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>SBIs/subject/year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Infections (Serious and Non-serious)</title>
        <time_frame>Up to 1 Year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Infections (Serious and Non-serious)</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>events per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Infections (All) per subject-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Serious Infections per subject-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Combined Days Lost</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Combined Days Lost</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Per Subject-Year</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Per Subject-Year</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unscheduled Visits to Physician/ER Due to Infections - Total Number of Visits</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unscheduled Visits to Physician/ER Due to Infections - Total Number of Visits</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Number of Visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unscheduled Visits to Physician/ER Due to Infections - Per Subject-Year</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unscheduled Visits to Physician/ER Due to Infections - Per Subject-Year</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Number of Visits per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Infections - Duration Per Infection</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Infections - Duration Per Infection</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="27.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Infections - Infection Days Per Subject</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Infections - Infection Days Per Subject</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days per subject</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="86.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations Due to Infections</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations Due to Infections</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Number of hospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations Due to Infections - Per Subject-Year</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations Due to Infections - Per Subject-Year</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Hospitalizations per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Hospitalization Due to Infections</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Hospitalization Due to Infections</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Hospitalization Due to Infections - Per Subject-Year</title>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Hospitalization Due to Infections - Per Subject-Year</title>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection)</title>
        <description>Summary of the days of antibiotic therapy in the study for prophylaxis, as treatment for infections, and combined</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection)</title>
          <description>Summary of the days of antibiotic therapy in the study for prophylaxis, as treatment for infections, and combined</description>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total days of antibiotic use COMBINED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total days of antibiotic use for INFECTION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total days of antibiotic use for PROPHYLAXIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection) - Per Subject-Year</title>
        <description>Summary of the days of antibiotic therapy in the study for prophylaxis, as treatment for infections, and combined, per subject-year of treatment with RI-002</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection) - Per Subject-Year</title>
          <description>Summary of the days of antibiotic therapy in the study for prophylaxis, as treatment for infections, and combined, per subject-year of treatment with RI-002</description>
          <population>Analysis included 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days of antibiotic use per subject-year COMBINED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of antibiotic per subject-year for INFECTION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of antibiotic per subject-yr for PROPHYLAXIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Trough Level of RI-002 and Serious and Non-serious Infections</title>
        <description>The relationship between trough IgG concentrations and the number of infections of any kind/seriousness was evaluated using Pearson linear correlation coefficients using forward analysis (outcomes after infusion) and backward analysis (outcomes prior to infusion; outcomes post last infusion were excluded)</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Trough Level of RI-002 and Serious and Non-serious Infections</title>
          <description>The relationship between trough IgG concentrations and the number of infections of any kind/seriousness was evaluated using Pearson linear correlation coefficients using forward analysis (outcomes after infusion) and backward analysis (outcomes prior to infusion; outcomes post last infusion were excluded)</description>
          <units>Linear Correlation Coefficients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Forward analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Backward analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - IgG</title>
        <description>Summary of trough total IgG concentration prior to specified infusion</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - IgG</title>
          <description>Summary of trough total IgG concentration prior to specified infusion</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000" spread="36.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 2 (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1024.3" spread="33.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 3 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1007.5" spread="33.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1017.4" spread="34.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 5 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1008.1" spread="32.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 6 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016.1" spread="34.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 7 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1039.5" spread="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="957.7" spread="35.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 9 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1030.5" spread="36.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 10 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1021.7" spread="37.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 11 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1018.9" spread="34.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000.6" spread="33.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 13 (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="992.8" spread="35.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 14 (3-week cycle only) (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1165.3" spread="79.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 15 (3-week cycle only) (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1160.9" spread="77.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 16 (3-week cycle only) (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1147.9" spread="74.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 17 (3-week cycle only) (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1136.3" spread="70.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Haemophilus Influenzae Type B</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Haemophilus influenzae type B</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Haemophilus Influenzae Type B</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Haemophilus influenzae type B</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="0.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="0.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Respiratory Syncytial Virus (RSV)</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Respiratory Syncytial Virus (RSV)</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 51-56 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Respiratory Syncytial Virus (RSV)</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Respiratory Syncytial Virus (RSV)</description>
          <population>Number available for analysis varied by infusion; 51-56 subjects</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1211.9" spread="187.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2220.1" spread="286.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1936.2" spread="363.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1632.4" spread="224.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1862.3" spread="207.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Tetanus</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Tetanus</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Tetanus</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Tetanus</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="0.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" spread="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 1</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 1</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 1</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 1</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.108" spread="0.5967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.900" spread="0.4585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.866" spread="0.5154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.788" spread="0.6185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.736" spread="0.5030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 3</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 3</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 3</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 3</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.447" spread="0.1077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.873" spread="0.1263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.787" spread="0.1105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.686" spread="0.1360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.672" spread="0.1249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 4</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 4</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-58 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 4</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 4</description>
          <population>Number available for analysis varied by infusion; 53-58 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.530" spread="0.0713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.824" spread="0.1589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.610" spread="0.0624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.644" spread="0.0703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.802" spread="0.1681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 5</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 5</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 52-58 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 5</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 5</description>
          <population>Number available for analysis varied by infusion; 52-58 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.843" spread="0.7116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.264" spread="0.8885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.235" spread="0.8974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.707" spread="0.8858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.503" spread="0.8420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 6B</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 6B</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 6B</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 6B</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.121" spread="0.2529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.496" spread="0.2503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.166" spread="0.1849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.026" spread="0.2199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.862" spread="0.2054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 7F</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 7F</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-57 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 7F</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 7F</description>
          <population>Number available for analysis varied by infusion; 53-57 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.413" spread="0.4009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.457" spread="0.3930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.633" spread="0.1971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.492" spread="0.2703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.191" spread="0.4040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 9V</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 9V</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 9V</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 9V</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.473" spread="0.1063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.938" spread="0.1566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.010" spread="0.2842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.902" spread="0.1579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.223" spread="0.3123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 14</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 14</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 14</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 14</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.853" spread="0.4724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.744" spread="0.3984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.356" spread="0.3547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.341" spread="0.4275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.218" spread="0.4268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 18C</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 18C</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 18C</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 18C</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.259" spread="0.7462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.461" spread="0.6143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.588" spread="0.5627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.146" spread="0.7852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.566" spread="0.5452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19A</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 19A</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 51-54 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19A</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 19A</description>
          <population>Number available for analysis varied by infusion; 51-54 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.090" spread="1.6428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.717" spread="1.3715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.450" spread="1.2636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.621" spread="1.0681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.167" spread="1.4398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19F</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 19F</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19F</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 19F</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.630" spread="1.0784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.876" spread="0.8826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.361" spread="0.8704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.042" spread="0.7610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.681" spread="0.9497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 23F</title>
        <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 23F</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Number available for analysis varied by infusion; 53-59 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 23F</title>
          <description>Summary of trough antibody concentrations prior to specified infusion for Streptococcus Pneumoniae, Serotype 23F</description>
          <population>Number available for analysis varied by infusion; 53-59 subjects</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.490" spread="0.1453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.829" spread="0.1548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.580" spread="0.1128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 12 (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.554" spread="0.1179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (Infusion 13 / 17) (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.681" spread="0.1282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Days Lost From Work/School/Daycare Due to Infections and Their Treatment</title>
        <description>Additional analysis performed to separate the number of days lost from work, school and/or daycare from the days missed from normal activities, due to infection</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis includes 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Lost From Work/School/Daycare Due to Infections and Their Treatment</title>
          <description>Additional analysis performed to separate the number of days lost from work, school and/or daycare from the days missed from normal activities, due to infection</description>
          <population>Analysis includes 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Days Lost From Work/School/Daycare Due to Infections and Their Treatment - Per Subject-Year</title>
        <description>Additional analysis performed to separate the number of days lost from work, school and/or daycare from the days missed from normal activities, due to infection</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis includes 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Lost From Work/School/Daycare Due to Infections and Their Treatment - Per Subject-Year</title>
          <description>Additional analysis performed to separate the number of days lost from work, school and/or daycare from the days missed from normal activities, due to infection</description>
          <population>Analysis includes 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>Days per subject-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants With No Days Lost From Work/School/Daycare Due to Infections and Their Treatment</title>
        <description>Additional analysis performed to separate the number of days lost from work, school and/or daycare from the days missed from normal activities, due to infection. Presenting the number of subjects with no (0) days lost from work/school/daycare due to infection</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Analysis includes 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
        <group_list>
          <group group_id="O1">
            <title>RI-002 Treatment</title>
            <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Days Lost From Work/School/Daycare Due to Infections and Their Treatment</title>
          <description>Additional analysis performed to separate the number of days lost from work, school and/or daycare from the days missed from normal activities, due to infection. Presenting the number of subjects with no (0) days lost from work/school/daycare due to infection</description>
          <population>Analysis includes 59 treated subjects, with a total of 55.88 subject-years of treatment with RI-002</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were treated with RI-002 every 3 or 4-weeks for up to 12 months, with Adverse Events reported from time of consent through the last study follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RI-002 Treatment</title>
          <description>Drug: RI-002 Dose: 300-800 mg/kg infusion
RI-002</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Following the first publication (sponsor coordinated), the Institution/PI may publish data or results from the study, if the material is reviewed by the sponsor at least 60 days prior to the proposed deadline; sponsor may remove any information considered confidential other than study data and results. If a multi-center publication is not submitted within 24 months after conclusion of the study at all sites, the Institution/PI may publish the study results following review by the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jimmy Mond, M.D., Ph.D</name_or_title>
      <organization>ADMA Biologics</organization>
      <phone>201-478-5552</phone>
      <email>jmond@admabio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

